IRO Systems Review Report Sample Clauses
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A above, the report shall include the following items:
1) a description of the documentation (including policies) reviewed and any personnel interviewed;
2) a detailed description of GSK’s systems, policies, processes, and procedures relating to the items identified in Sections II.A.1-15 above, including a general description of GSK’s control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review performed. For each of the Reviewed Policies and Procedures identified in Section B above, the report shall include the following items:
1. a description of the documentation (including policies) reviewed and any personnel interviewed;
2. a detailed description of Life Spine’s systems, policies, processes, and procedures relating to the items identified in Sections B.1-10 above, including a general description of Life Spine's control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections B.1-10 above are made known or disseminated within Life Spine;
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review, which shall contain the following information.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A and II.B above, the report shall include the following items:
1. a description of the documentation (including policies) reviewed and any personnel interviewed;
2. a detailed description of systems, policies, processes, and procedures relating to the items identified in Sections II.A and II.B. above, including a general description of the control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections II.A and II.B above are made known or disseminated within the USWM;
4. a detailed description of any system(s) used to track and respond to requests for information about Government Reimbursed Products;
5. a detailed description of the incentive compensation system for Covered Persons who are sales representatives, including a description of the bases upon which compensation is determined. To the extent that USWM may establish compensation differently for individual products, the IRO shall report separately on each such type of compensation arrangement;
6. a detailed description of any system(s) used to track requests for donations or other assistance from any Independent Charity PAP;
7. a detailed description of any system(s) used to track donations or other assistance provided in response to requests from Independent Charity PAPs;
8. a detailed description of any system(s) used to track requests for donations or other assistance from or through any Pharmaceutical Manufacturer PAP;
9. a detailed description of any system(s) used to track donations or other assistance provided in response to requests from or through any Pharmaceutical Manufacturer PAP;
10. findings and supporting rationale regarding any weaknesses in the systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and
11. recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A above, the report shall include the following items:
1. a description of the documentation (including policies) reviewed and any personnel interviewed;
2. a detailed description of systems, policies, processes, and procedures relating to the items identified in Section II.A above, including a general description of the control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Section II.A above are made known or disseminated within the Indivior;
4. a detailed description of any system(s) used to track and respond to requests for information about Government Reimbursed Products;
5. a detailed description of the incentive compensation system for Covered Persons who are sales representatives and their direct managers, including a description of the bases upon which compensation is determined. To the extent that Indivior may establish compensation differently for individual products, the IRO shall report separately on each such type of compensation arrangement;
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review performed. For each of the Reviewed Policies and Procedures identified in Section B above, the report shall include the following items:
1. a description of the documentation (including policies) reviewed and any personnel interviewed;
2. a detailed description of Merit's systems, policies, processes, and procedures relating to the items identified in Sections B.1-10 above, including a general description of Merit's control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections B.1-10 above are made known or disseminated within Merit;
4. findings and supporting rationale regarding any weaknesses. in Merit's systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and
5. recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II. above, the report shall include the following items:
1) description of the documentation (including policies) reviewed and any personnel interviewed;
2) a detailed description of Daiichi’s systems, policies, processes, and procedures relating to the items identified in Sections II.1-12 above, including a general description of Daiichi’s control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3) a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections II.1-12 above are made known or disseminated within Daiichi;
4) a detailed description of Daiichi’s incentive compensation system for Covered Persons who are sales representatives, including a description of the bases upon which compensation is determined and the extent to which compensation is based on product performance. To the extent that Daiichi may establish compensation differently for individual products, the IRO shall report separately on each such type of compensation arrangement;
5) findings and supporting rationale regarding any weaknesses in Daiichi’s systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any;
6) recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any;
7) whether the risk monitoring and risk mitigation action associated with RAMP identify relevant risks and address identified risks;
8) whether sufficient controls exist to ensure that all monitoring and auditing activities and risk mitigation action items are tracked appropriately;
9) whether the RAMP (including the options for risk mitigation activities) potentially mitigates identified risks; and
10) whether sufficient controls exist to ensure that all agreed-upon risk monitoring and audit activities and risk mitigation action items are completed as planned pursuant to the RAMP.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A above, the report shall include the following items:
1) a description of the documentation (including policies) reviewed and any personnel interviewed;
2) a detailed description of GSK’s systems, policies, processes, and procedures relating to the items identified in Sections II.A.1-15 above, including a general description of GSK’s control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3) a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections II.A.1-15 above are made known or disseminated within GSK;
4) a detailed description of any system(s) used to track and respond to requests for information about Government Reimbursed Products (including the Inquiries Database);
5) findings and supporting rationale regarding any weaknesses in GSK’s systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and
6) recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II above, the report shall include the following items:
1) a description of the documentation (including policies) reviewed and any personnel interviewed;
2) a detailed description of Jazz’s systems, policies, processes, and procedures relating to the items identified in Sections II.1-2 above, including a general description of Jazz’s control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3) a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections II.1-2 above are made known or disseminated within Jazz;
4) a detailed description of any system(s) used to track requests for donations or other assistance from any Independent Charity PAP;
5) a detailed description of any system(s) used to track donations or other assistance provided in response to requests from Independent Charity PAPs;
6) a detailed description of any system(s) used to track assistance provided through any Pharmaceutical Manufacturer PAP;
7) findings and supporting rationale regarding any weaknesses in Jazz’s systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and
8) recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.
IRO Systems Review Report. The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed Policies and Procedures identified in Section II.A above, the report shall include the following items:
1) a description of the documentation (including policies) reviewed and any personnel interviewed;
2) a detailed description of Novartis’ systems, policies, processes, and procedures relating to the items identified in Sections II.A. 1-11 above, including a general description of Novartis’ control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;
3) a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections II.A. 1-11 above are made known or disseminated within Novartis;
4) a detailed description of any system(s) used to track and respond to requests for information about Novartis’ Government Reimbursed Products (including the Inquiries Database);
5) a detailed description of Novartis’ incentive compensation system for Relevant Covered Persons who are sales representatives, including a description of the bases upon which compensation is determined and the extent to which compensation is based on product performance. To the extent that Novartis may establish compensation differently for individual products, the IRO shall report separately on each such type of compensation arrangement;
6) findings and supporting rationale regarding any weaknesses in Novartis’ systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and
7) recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.